Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR - Hesselbarth, David; D’Orazio, Michelle; Ciccarone, Giovanni; Gjermeni, Diona; Jülch, Carina; Wessinger, Marius; Maslarska, Mariya; Rilinger, Jonathan; Hilgendorf, Ingo; Wolf, Dennis; Kaier, Klaus; Dürschmied, Daniel; et al. (Clinical research in cardiology, 2025)
Online veröffentlicht: 6. Oktober 2025